Sollievo Pharmaceuticals

Sollievo Pharmaceuticals

Closed: Dec. 2022

About this raise

Sollievo Pharmaceuticals, with a valuation of $20 million, is raising funds on StartEngine. The company has developed a fast-acting sedative in the form of an injectable benzodiazepine. The sedative, Proviza, causes rapid sedation in agitated and aggressive patients and protects healthcare staff from injuries and abuse. Proviza is highly water-soluble and brings about sedation in 5-10 minutes. Robert Schultz founded Sollievo Pharmaceuticals in February 2018. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000. The campaign proceeds will be used for the completion of the patient clinical trial, submission of the New Drug Application, and receiving FDA approval.

Expand

Investment Overview

Invested this round: $40,715

Deal Terms

Total Commitments

Platform
StartEngine
Start Date
08/05/2022
Close Date
12/16/2022
Min. Goal
$10,000
Max Goal
$1,070,000
Min. Investment

$400

Security Type

Equity - Common

Company Stage

Early Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$20,000,000

Company & Team

Company

Year Founded
2018
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Location
San Juan Capistrano, California
Business Type
Growth
Company Website
Visit Website

Team

Employees
1
Prior Founder Exits?
No
Founder Name
Robert Schultz
Title
President, CEO and Director

Financials

 Revenue
$0
 Monthly Burn
$15,790
 Runway
0 months

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-189,478

$-1,164,009

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$153

$1,157

Accounts Receivable

$0

$0

Total Assets

$153

$1,157

Short-Term Debt

$772,225

$655,821

Long-Term Debt

$1,252,890

$1,180,819

Total Liabilities

$2,025,115

$1,836,640

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$0
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
12/16/2022 StartEngine $20,000,000 $40,715 Equity - Common Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Sollievo Pharmaceuticals on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $20,000,000
Price per Share: $2.00

Follow company

Follow Sollievo Pharmaceuticals on StartEngine 2022

Buy Sollievo Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Sollievo Pharmaceuticals may no longer be accepting investments.

Sollievo Pharmaceuticals Deal Report

Get Kingscrowd's comprehensive report on Sollievo Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sollievo Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sollievo Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge